Takeda Pharmaceutical Co. Ltd. has raised is full fiscal year forecast for net profit attributable to owners of the company by a sizable JPY56.5bn ($535m), or 46%, to JPY180.5bn, due mainly to lower tax costs associated with on-going integration and optimization of the legal entities within its organizational structure.
Takeda Expects Stronger Net Profit On Lower Tax
Entyvio Again Drives Growth In Q3
Entyvio strong again for Japanese firm as it raises net profit forecast on lower tax costs. Meanwhile, 'Wave 1' pipeline projects are progressing, with simultaneous development in major markets a key goal.
More from Business
More from Scrip
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.